Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs-Reference-Cited by-同舟云学术

Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs

Published:2014-11-28 Issue:2 Volume:74 Page:474-475
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Vogelzang E H,Pouw M F,Nurmohamed M,Kneepkens E L,Rispens T,Wolbink G J,Krieckaert C L M

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference7 articles.

1. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis;Bartelds;Ann Rheum Dis,2007

2. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up;Vogelzang;Ann Rheum Dis,2014

3. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up;Bartelds;JAMA,2011

4. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner;Krieckaert;Ann Rheum Dis,2012

5. Key findings towards optimising adalimumab treatment: the concetration-effect curve;Pouw;Ann Rheum Dis

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of Adalimumab Therapy for Ankylosing Spondylitis;Current Rheumatology Reviews;2024-12

2. Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients;Current Opinion in Pharmacology;2023-02

3. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine;BioDrugs;2022-10-31

4. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider;RMD Open;2022-06

5. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases;Annals of the Rheumatic Diseases;2022-05-12